{
    "pmcid": "8223476",
    "qa_pairs": {
        "What biophysical properties were highlighted as favorable for the therapeutic application of the nanobodies?": [
            "High stability, solubility, and low non-specific binding",
            "High affinity, low solubility, and high non-specific binding",
            "Low stability, high solubility, and high non-specific binding",
            "High stability, low solubility, and low non-specific binding"
        ],
        "What method was used to enhance the affinity and neutralization potency of nanobodies against SARS-CoV-2?": [
            "CDR swapping",
            "Random mutagenesis",
            "Phage display",
            "Rational design"
        ],
        "What was the key advantage of the CDR-swapping approach over traditional affinity maturation techniques?": [
            "Achieving comparable or better affinities and neutralization potencies",
            "Reducing the time required for nanobody development",
            "Increasing the diversity of the nanobody library",
            "Enhancing the solubility of nanobodies"
        ],
        "What was the specificity of the nanobody KC3.ep3 in terms of viral binding?": [
            "Specific to SARS-CoV-2 and did not bind to the RBD of SARS-CoV",
            "Specific to SARS-CoV and did not bind to the RBD of SARS-CoV-2",
            "Cross-reactive with both SARS-CoV and SARS-CoV-2",
            "Specific to MERS-CoV and did not bind to the RBD of SARS-CoV-2"
        ],
        "Which nanobody showed potent neutralization of both SARS-CoV-2 pseudovirus and live virus?": [
            "KC3.ep3",
            "KC3.ep1",
            "KC3.ep2",
            "KC3.ep4"
        ]
    }
}